
AEYE Health is a digital health company founded in 2018 that specializes in AI-based diagnostic screening for ocular diseases. Their flagship product, AEYE-DS, utilizes artificial intelligence to instantly diagnose diabetic retinopathy from retinal images using both handheld and tabletop cameras. The solution offers high accuracy (e.g., 93% sensitivity, 91% specificity with desktop cameras) and requires only one image per eye, often without dilation, enabling a 1-minute screening. AEYE Health aims to prevent blindness by making sight-saving screening accessible at the point of care, particularly for primary care physicians and in underserved communities. Their technology addresses care gaps, as only a small percentage of diabetic patients adhere to recommended screenings. The company's business model appears to be SaaS or licensing for its diagnostic screening technology.

AEYE Health is a digital health company founded in 2018 that specializes in AI-based diagnostic screening for ocular diseases. Their flagship product, AEYE-DS, utilizes artificial intelligence to instantly diagnose diabetic retinopathy from retinal images using both handheld and tabletop cameras. The solution offers high accuracy (e.g., 93% sensitivity, 91% specificity with desktop cameras) and requires only one image per eye, often without dilation, enabling a 1-minute screening. AEYE Health aims to prevent blindness by making sight-saving screening accessible at the point of care, particularly for primary care physicians and in underserved communities. Their technology addresses care gaps, as only a small percentage of diabetic patients adhere to recommended screenings. The company's business model appears to be SaaS or licensing for its diagnostic screening technology.
Flagship product: AEYE-DS — an FDA-cleared, fully autonomous AI diagnostic for diabetic retinopathy that supports handheld and tabletop retinal cameras and returns results in about 1 minute.
Mission / focus: Point-of-care retinal screening to expand access to sight‑saving screening (primary care and underserved settings).
Regulatory / reimbursement: FDA clearance for autonomous diabetic retinopathy screening; screening can be reimbursed under CPT 92229.
Founding: Founded in 2019 and based in New York City.
Funding signal: At least two funding rounds reported (Angel Nov 2018; Seed Jan 2022); amounts not publicly disclosed in accessible profiles.
Investor / board signal: Described as venture-backed; board members listed with affiliations to Helios Global Investments, Falcon Ventures, and OurCrowd.
Retinal (fundus) imaging and automated screening for diabetic retinopathy and other ocular/systemic disease signals at point of care.
2019
Digital health
Amounts not publicly disclosed in accessible company profiles.
“Venture-backed; company website lists board members with affiliations to Helios Global Investments, Falcon Ventures, and OurCrowd.”